Physician profile

Sujoy Gill

Pulmonary Disease · Richmond, VA

NPI 1225246861

$295,521.26

in general payments reported to CMS, 2019-2025

45 companies · $107K in 2025

The $107K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$150,950.11
Travel and Lodging$17,310.98
Food and Beverage$11,553.14
Education$5,723.94
Honoraria$4,800.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $158,510.48 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $48,482.16 2019-2025 Tezspire, Fasenra, Airsupra
Grifols USA, LLC $25,416.60 2019-2025 Prolastin-C Liquid, Xembify
Mylan Specialty L.P. $25,196.68 2019-2024 Yupelri, Yupelri
Janssen Pharmaceuticals, INC $13,501.53 2020-2023 Xarelto
Verona Pharma, INC. $10,393.84 2025 Ohtuvayre
Intuitive Surgical, INC. $6,608.09 2024
Boehringer Ingelheim Pharmaceuticals, INC. $788.84 2019-2025 Ofev, Stiolto Respimat, Spiriva Respimat
Amgen INC. $747.29 2021-2025 Tezspire, Tavneos
Grifols Shared Services North America, INC. $736.33 2023-2025 Prolastin-C Liquid
Genentech USA, INC. $690.11 2019-2025 Xolair
Actelion Pharmaceuticals US, INC. $496.32 2020-2025 Uptravi, Opsumit, Opsynvi
Genzyme Corporation $466.51 2019-2025
Regeneron Healthcare Solutions, INC. $418.23 2019-2025 Dupixent
Mallinckrodt Hospital Products INC. $409.93 2020-2025 Acthar
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Ani Pharmaceuticals, INC. $403.20 2023-2025 Purified Cortrophin Gel
Insmed, INC. $324.52 2019-2025 Arikayce, Brinsupri
Merck Sharp & Dohme LLC $268.08 2019-2025 Winrevair
Novartis Pharmaceuticals Corporation $262.92 2019-2024
United Therapeutics Corporation $209.30 2021-2025 Tyvaso, Tyvaso
Takeda Pharmaceuticals U.S.A., INC. $205.19 2021-2025 Glassia
Pfizer INC. $113.79 2022-2025
Bayer Healthcare Pharmaceuticals INC. $111.14 2019-2025
Vifor Pharma, INC. $109.61 2019-2025 Zemaira
Baxter Healthcare $93.49 2022-2024 Hillrom - Monarch Airway Clearance System
Electromed, INC. $93.24 2019-2025 Smartvest
Paratek Pharmaceuticals, INC. $64.72 2021
Sunovion Pharmaceuticals INC. $41.10 2019
Viatris Specialty LLC $39.98 2025 Yupelri
Mallinckrodt Enterprises LLC $35.47 2019
Covidien LP $25.77 2019-2020
Atricure, INC. $25.58 2025 Atricure Cryoice Cryosphere Cryoablation System
Philips North America LLC $25.12 2020
Azurity Pharmaceuticals, INC. $24.38 2025 Alvesco
3b Medical, INC. $22.97 2025 Luna
Inogen, INC. $21.95 2023 Inogen One G5 Oxygen Concentrator - Bluetooth
Biogen, INC. $19.99 2025 Spinraza
Axsome Therapeutics, INC. $18.00 2023 Sunosi
Covis Pharma Gmbh $17.04 2022
Pharming Healthcare, INC. $15.42 2023 Ruconest
Gilead Sciences, INC. $15.01 2019
Pulmonx Corporation $14.09 2023 Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console
La Jolla Pharmaceutical Company $12.63 2022
Teva Pharmaceuticals USA, INC. $12.38 2021
Sandoz INC. $12.24 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sujoy Gill

$295,521.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $107K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/282352/sujoy-gill

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.